Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis
Jordan D. Deaner, Sunil K. Srivastava, Rula A. Hajj‐Ali, Careen Y. Lowder, Arthi Venkat, Kimberly Baynes, Sumit Sharma
Topics & Concepts
InfliximabBiosimilarMedicineUveitisDermatologyImmunologyInternal medicineTumor necrosis factor alphaOcular Diseases and Behçet’s SyndromeRetinal Diseases and TreatmentsRetinal and Optic Conditions